<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Plant Biol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Plant Biol</journal-id><journal-title-group><journal-title>Current Plant Biology</journal-title></journal-title-group><issn pub-type="epub">2214-6628</issn><publisher><publisher-name>The Authors. Published by Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7543902</article-id><article-id pub-id-type="pii">S2214-6628(20)30061-X</article-id><article-id pub-id-type="doi">10.1016/j.cpb.2020.100180</article-id><article-id pub-id-type="publisher-id">100180</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Challenges and future directions of potential natural products leads against 2019-nCoV outbreak</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Ospanov</surname><given-names>Meirambek</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Le&#x000f3;n</surname><given-names>Francisco</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Jenis</surname><given-names>Janar</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Khan</surname><given-names>IKhlas A.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Ibrahim</surname><given-names>Mohamed A.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref><xref rid="cor0005" ref-type="corresp">*</xref></contrib><aff id="aff0005"><label>a</label>National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA</aff><aff id="aff0010"><label>b</label>The Research Center for Medicinal Plants, Al-Farabi Kazakh National University, Al-Farabi ave. 71, 050040, Almaty, Kazakhstan</aff><aff id="aff0015"><label>c</label>Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA</aff><aff id="aff0020"><label>d</label>Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, 12622, Cairo, Egypt</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding authors at: National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.</corresp></author-notes><pub-date pub-type="pmc-release"><day>8</day><month>10</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>12</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>8</day><month>10</month><year>2020</year></pub-date><volume>24</volume><fpage>100180</fpage><lpage>100180</lpage><history><date date-type="received"><day>15</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>1</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0005"><p>Except for Remdesivir&#x000ae; no other drug or vaccine has yet been approved to treat the coronavirus disease (COVID-19) caused by the virus known as, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir&#x000ae; an small molecule and nucleic acid analogue, it is used to treat adults and children with laboratory confirmed COVID-19, only administrated in hospital settings. Small molecules and particularly natural products count for almost fifty percent of the commercially available drugs, several of them are marketed antiviral agents and those can be a potential agent to treat COVID-19 infections. This short review rationalized different key natural products with known activity against coronaviruses as potential leads against COVID-19.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>2019-nCoV</kwd><kwd>Natural products</kwd><kwd>SARS-CoV-2</kwd><kwd>Coronaviruses</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0005">Coronaviruses (CoVs) are the largest group of viruses belonging to the Nidovirales order, which includes Coronaviridae, Arteriviridae, and Roniviridae families. The Coronavirinae comprises one of two subfamilies in the Coronaviridae family, with the other being the Torovirinae [<xref rid="bib0005" ref-type="bibr">1</xref>]. Coronaviruses are named for the crown-like spikes on their surface and there are four main sub-groupings of coronaviruses, known as alpha, beta, gamma, and delta [<xref rid="bib0010" ref-type="bibr">2</xref>]. Human coronaviruses were first identified in the mid-1960&#x02032;s [<xref rid="bib0015" ref-type="bibr">3</xref>]. Coronaviruses cause acute and chronic respiratory, enteric and/or central nervous system diseases in many species, including humans [<xref rid="bib0020" ref-type="bibr">4</xref>].</p><p id="par0010">There are seven coronaviruses that can infect human worldwide, four common types are 229E and NL63 (alpha coronavirus), while OC43 and HKU1 (beta coronavirus). Sometimes animal coronaviruses can cross-species transmitted and infect humans [<xref rid="bib0025" ref-type="bibr">5</xref>]. Three recent examples of this are beta coronaviruses; SARS-CoV (causes severe acute respiratory syndrome, or SARS), MERS-CoV (causes Middle East respiratory syndrome, or MERS), and the recently named by World Health Organization (WHO) as SARS-CoV-2 coronavirus causing the disease called COVID-19 [<xref rid="bib0030" ref-type="bibr">6</xref>]. Porcine transmissible gastroenteritis virus (TGEV), human coronavirus (HCoV) 229E, mouse hepatitis virus (MHV), bovine coronavirus (BCoV), and porcine epidemic diarrhea virus (PEDV) all belong to the coronaviridae family. These coronaviruses are encompassed, positive single-abandoned RNA infections containing 27&#x02013;31 kb genomes, which cause respiratory and enteric maladies in people and animals [<xref rid="bib0035" ref-type="bibr">7</xref>].</p><p id="par0015">Currently, it is difficult to generate animal models capable to simulate the key features for the human disease. These models are aiming to find the pathogenic mechanism, search for avenues to identify targets on the virus suitable for attack and design successful treatments. SARS-CoV is capable to readily infect laboratory mice, but, it does not cause any significant disease symptoms unless the virus is transmitted for adaptation into the mouse host [<xref rid="bib0040" ref-type="bibr">8</xref>]. Moreover, infection of primates produces a milder disease than that observed in humans, although fever and pulmonary inflammation were noted [<xref rid="bib0045" ref-type="bibr">9</xref>].</p><p id="par0020">On March 11, 2020, The World Health Organization (WHO) has declared the novel coronavirus (COVID-19) outbreak a global pandemic. On March 28, 2020, United States Food and Drug Administration (FDA) issued an emergency use authorization of hydroxychloroquine sulfate (Plaquenil&#x000ae;, Quineprox&#x000ae;), chloroquine phosphate (Aralen&#x000ae;), in which the physicians can prescribe those to seriously hospitalized COVID-19 patients. Later in June 15, 2020 FDA revoked their use based on serious side effects and no real benefits on clinical trials [<xref rid="bib0050" ref-type="bibr">10</xref>]. As of September 28, 2020, the coronavirus disease 2019 (COVID-19) pandemic had resulted in 33,270,108 cases and 1,001,497 deaths worldwide, including 7,317,312 cases and 209,423 deaths in the United States (US) [<xref rid="bib0055" ref-type="bibr">11</xref>].</p><p id="par0025">Drugs currently being investigated for the possibility of use against CoV disease include monoclonal antibodies, direct-acting antivirals (DAAs) such as protease, helicase, and polymerase inhibitors, and immunomodulators such as interferons and corticosteroids. Challenges in the development of CoV antivirals are both general to RNA viruses and specific to CoVs. The process of replication of positive-sense RNA virus genomes is generally characterized by high error rates, high viral yields, short replication times, and abundant homologous and nonhomologous recombination [<xref rid="bib0060" ref-type="bibr">12</xref>]. Given the urgency of the COVID-19 outbreak, we focus here in this report, on the potential to repurpose existing natural antiviral and anticancer agents with established activity against various coronaviruses such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [<xref rid="bib0065" ref-type="bibr">13</xref>].</p><sec id="sec0010"><label>1.1</label><title>Approved small molecules to treat COVID-19</title><p id="par0030">Natural compounds are potential sources for the development of antiviral agents. Various medicinal herbs producing anti-inflammatory, antifungal, and antitumor activities have been extensively studied in order to identify the herbs possessing antiviral properties. Indeed, chloroquine, the first small molecule Food and Drug Administration (FDA) approved to treat COVID-19, later revoked, was inspired and developed from quinine sharing the same quinoline core (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>
). Quinine is the bioactive component, an old antimalarial agent, it was isolated from the bark of <italic>Cinchona officinalis</italic> used for centuries by the Inca empire in South America to treat malaria and other illness [<xref rid="bib0070" ref-type="bibr">14</xref>].<fig id="fig0005"><label>Fig. 1</label><caption><p>Quinine and chloroquine chemical structures, dashed ellipse corresponded to the quinoline core.</p></caption><alt-text id="at0040">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0035">Remdesivir&#x000ae; possessed broad activity against RNA viruses; many research groups assessed its antiviral activity both <italic>in vitro</italic> and <italic>in vivo</italic>, validating its activity against coronaviruses. Its antiviral activity was confirmed against SARS, MERS zoonotic coronaviruses, as well as the circulating human coronaviruses HCoV&#x02212;OC43 and HCoV-229E, which cause common human cold. <italic>In vitro</italic> and preclinical <italic>in vivo</italic> animal models supported the effectiveness of Remdesivir&#x000ae; against SARS-CoV-2 and related coronaviruses. These include a recent <italic>in vitro</italic> study of Remdesivir&#x000ae; assessing antiviral activity against SARS-CoV-2 using qRT-PCR quantification of viral copy number in infected Vero E6 cells. This study demonstrated an IC<sub>50</sub> of 770 nM and an IC<sub>90</sub> equal to 1760 nM (with cytotoxic concentration &#x0003e;100 mM). The mechanism of action of Remdesivir&#x000ae; is attacking a weak point of viral replication within the host, such as targeting the divergent RNA-dependent RNA polymerase (RdRp). The chemical structure for Remdesivir&#x000ae; resembles adenosine one (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>
). Imagining under cryo-electron microscopy confirm Remdesivir&#x000ae; latches onto the primer RNA of the virus shutting down the viral reproduction [<xref rid="bib0075" ref-type="bibr">15</xref>].<fig id="fig0010"><label>Fig. 2</label><caption><p>Chemical structures of Remdesivir&#x000ae; and adenosine.</p></caption><alt-text id="at0045">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="par0040">Recently, Y. Wang et al. reported randomized, double-blind, placebo-controlled trial in hospitalized adults with severe COVID-19 in China. Adverse effects such as constipation, hypoalbuminemia, hypokalemia, anemia, and thrombocytopenia as well as increased total bilirubin concentrations were reported in 66 % of patients who received Remdesivir&#x000ae;. Serious adverse events reported in 18 %, and drug discontinued because of the adverse events [<xref rid="bib0080" ref-type="bibr">16</xref>].</p><p id="par0045">Next section is a compilation of the natural products that have been shown to be active against the coronavirus affecting the human health. The compounds are grouped according to their biosynthetic origin.</p></sec><sec id="sec0015"><label>1.2</label><title>Natural Products showing activity against coronaviruses</title><sec id="sec0020"><label>1.2.1</label><title>Alkaloids</title><p id="par0050">Several alkaloids have shown antiviral activity, for example, Kim et al. 2019, showed that <italic>bis</italic>-benzylisoquinoline alkaloids such as, tetrandrine (<bold>1</bold>), fangchinoline (<bold>2</bold>), and cepharanthine (<bold>3</bold>) isolated from <italic>Stephania tetrandra</italic> and other related species of <italic>Menispermaceae</italic>, (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>
) to have potent activity against human coronavirus OC43 infection. Interestingly, <italic>bis</italic>-benzylisoquinoline alkaloids are enriched in several well-known edible plants such as <italic>Nelumbo nucifera</italic> (lotus) which is widely cultivated in Asia [<xref rid="bib0085" ref-type="bibr">17</xref>]. Tetrandrine (<bold>1</bold>) and fangchinoline (<bold>2</bold>) showed <italic>in vitro</italic> antiviral activity against human coronavirus [<xref rid="bib0090" ref-type="bibr">18</xref>]. The expression levels of the <italic>S-</italic> and <italic>N</italic>-proteins in MRC-5 lung human cells infected with HCoV&#x02212;OC43 at two days&#x02019; post-infection were significantly diminished and virus replication was suppressed by the action of alkaloids <bold>1-3</bold>. These alkaloids did not show cytotoxic effects on MRC-5 cells up to 10 &#x003bc;M (CC<sub>50</sub> &#x0003e; 10 &#x003bc;M). The IC<sub>50</sub> values of tetrandrine (<bold>1</bold>), fangchinoline (<bold>2</bold>), and cepharanthine (<bold>3</bold>) were 0.33 &#x000b1; 0.03, 1.01 &#x000b1; 0.07, and 0.83 &#x000b1; 0.07 &#x003bc;M, respectively [<xref rid="bib0095" ref-type="bibr">19</xref>]. This in turn demonstrated that tetrandrine (<bold>1</bold>), fangchinoline (<bold>2</bold>), and cepharanthine (<bold>3</bold>) inhibited HCoV&#x02212;OC43 at the early stage of infection which is mainly due to suppression of the replication of HCoV&#x02212;OC43 virus [<xref rid="bib0095" ref-type="bibr">19</xref>].<fig id="fig0015"><label>Fig. 3</label><caption><p>Chemical structure for selected alkaloids and sinigrin.</p></caption><alt-text id="at0050">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p><p id="par0055">Tetrandrine (<bold>1</bold>) has been known as antagonist of calmodulin, has anti-tumor, anti-inflammatory effects, and can effectively inhibit fibroblasts and thereby inhibiting pulmonary fibrosis [<xref rid="bib0100" ref-type="bibr">20</xref>]. Since the 1950s, tetrandrine (<bold>1</bold>) has been used in China as an antihypertensive drug. In 1970s, tetrandrine (<bold>1</bold>) underwent a phase I clinical trial as an antitumor drug in US. Although tetrandrine is not in clinical use in countries other than mainland China, it has been used in research worldwide showing to have multiple pharmacological activities including immunosuppression, antihypertensive, and antitumor activities. Tetrandrine had a synergistic effect on the cytotoxicity of the chemotherapeutic agents; 5-fluorouracil, oxaliplatin, and docetaxel in two gastric cancer cell lines [<xref rid="bib0105" ref-type="bibr">21</xref>]. Fangchinoline (<bold>2</bold>) is known to have inhibitory effects on histamine release and on the production of IL-1 and tumor necrosis factor-a (TNF-<italic>&#x003b1;</italic>). Also, fangchinoline was identified as capable of inhibiting PI3K and its downstream signaling pathways and suppressing PI3K-mediated SGC7901 behavior including growth, migration, and invasion. Further testing in experimental <italic>in vivo</italic> models is warranted [<xref rid="bib0110" ref-type="bibr">22</xref>].</p><p id="par0060">In an extensive study, more than 200 Chinese medicinal herb extracts were screened for antiviral activities against (SARS-CoV) using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay for virus-induced cytopathic effect (CPE) [<xref rid="bib0095" ref-type="bibr">19</xref>]. The extracts of <italic>Lycoris radiata</italic>, <italic>Artemisia annua</italic>, <italic>Pyrrosia lingua</italic>, and <italic>Lindera aggregata</italic> showed potent antiviral activities against SARS-CoV strain BJ001 with 50 % effective concentration (EC<sub>50</sub>) 2.4 &#x000b1; 0.2, 34.5 &#x000b1; 2.6, 43.2 &#x000b1; 14.1, and 88.2 &#x000b1; 7.7 &#x003bc;g/mL, respectively. Among those extracts, <italic>L. radiata</italic> extract showed the best inhibition effect in SARS-CoV bioassay guided fractionation yielded lycorine (<bold>4</bold>) as the main bioactive components (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). The EC<sub>50</sub> value for lycorine (<bold>4</bold>) was found to be 15.7 &#x000b1; 1.2 nM. The CC<sub>50</sub> of lycorine (<bold>4</bold>) in Vero E6 and HepG2 cells were 14980.0 &#x000b1; 912.0 and 18810.0 &#x000b1; 1322.0 nM, respectively [<xref rid="bib0115" ref-type="bibr">23</xref>]. Lycorine (<bold>4</bold>) can cause toxic effects at low doses in canines&#x02019; model (&#x0223c; 1 mg/kg), further development of this compound as a potential drug candidate is needed, and the mechanism of its antiviral activity is still not clear [<xref rid="bib0120" ref-type="bibr">24</xref>].</p><p id="par0065">
<italic>Isatis indigotica</italic> root is a Chinese herb frequently used for the prevention of SARS during the SARS outbreaks in China, Hong Kong, and Taiwan. The main components of <italic>I. indigotica</italic> root are the alkaloids; indigo (<bold>5</bold>), indirubin (<bold>6</bold>), and indican (indoxyl-<italic>&#x003b2;</italic>-<sc>d</sc>-glucoside) (<bold>7</bold>), and the allyl glucosinate, sinigrin (<bold>8</bold>) (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). Indigo (<bold>5</bold>) and indirubin (<bold>6</bold>) were identified as the promiscuous chymotrypsin inhibitors [<xref rid="bib0125" ref-type="bibr">25</xref>]. C.W. Lin et al. [<xref rid="bib0130" ref-type="bibr">26</xref>] characterized the anti-SARS-CoV 3CL<sup>pro</sup> effect of the water extract of <italic>I. indigotica</italic> root-derived compounds. Of the five compounds that were tested <italic>in vitro</italic>, sinigrin (<bold>8</bold>) and indigo (<bold>5</bold>) showed dose-dependently inhibited cleavage activities of the 3CL<sup>pro</sup> in cell-free and cell-based assays. The IC<sub>50</sub> values in the cell-free assays were 121 &#x003bc;M for sinigrin and 300 &#x003bc;M for indigo. The cell-based assay indicated that sinigrin (IC<sub>50</sub> = 217 &#x003bc;M) was more efficient in blocking the cleavage processing of the 3CL<sup>pro</sup> than indigo (IC<sub>50</sub> = 752 &#x003bc;M). Sinigrin (<bold>8</bold>) is a component in many edible plants of the <italic>Brassicaceae</italic> family, such as broccoli and Brussels sprouts. In seeds of <italic>Brassica nigra</italic> (mustard seeds) sinigrin <bold>(8)</bold> is found in high concentration, mustard has been used for centuries by mankind for its culinary, as well as various medicinal properties [<xref rid="bib0135" ref-type="bibr">27</xref>].</p></sec><sec id="sec0025"><label>1.2.2</label><title>Flavonoids</title><p id="par0070">In 2005, Lin et al. studied phenolic compounds which were evaluated for their inhibitory effects on the SARS- CoV 3CL<sup>pro</sup>. Aloe-emodin (<bold>9</bold>) and hesperetin (<bold>10</bold>) dose-dependently inhibited cleavage activity of the 3CL<sup>pro</sup> in <italic>in vitro cell</italic>-free and cell-based assays, the IC<sub>50</sub> values of aloe-emodin (<bold>9</bold>) and hesperetin (<bold>10</bold>) were 132 &#x003bc;M and 60 &#x003bc;M, respectively [<xref rid="bib0130" ref-type="bibr">26</xref>].</p><p id="par0075">The expression of nucleocapsid (N) protein essential for MERS-CoV replication was decreased after resveratrol treatment, down regulating the apoptosis induced by MERS-CoV <italic>in vitro</italic> assay [<xref rid="bib0140" ref-type="bibr">28</xref>]. Resveratrol also has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, and reversible manner [<xref rid="bib0145" ref-type="bibr">29</xref>]. In several toxicity studies, resveratrol was orally administrated at its maximum tolerated doses to access its adverse effects; the results show the lack of carcinogenicity. Reports revealed the absence of acute skin and eye irritation or other allergenicity signs that could be caused by the compound. Despite being an estrogen-like compound, studies provide further evidence that <italic>trans</italic>-resveratrol has low estrogenic potency <italic>in vivo</italic> [<xref rid="bib0150" ref-type="bibr">30</xref>]. A large amount of resveratrol is produced in the skin of grapes to protect the plant against fungal diseases and sun damage [<xref rid="bib0155" ref-type="bibr">31</xref>]. Resveratrol is widely available on red wine extract, grape seed extract, and Japanese knotweed extract and others. Most supplements on the market are derived from Japanese knotweed as it has the highest concentrations of resveratrol in nature [<xref rid="bib0160" ref-type="bibr">32</xref>]. Commercial dietary supplements contain an average between 50&#x02013;500 mg of <italic>trans</italic>-resveratrol (<bold>11</bold>), human clinical studies have also been performed up to single doses of 5 g of resveratrol without observing adverse effects [<xref rid="bib0150" ref-type="bibr">30</xref>]. These data suggest that <italic>trans</italic>-resveratrol (<bold>11</bold>) is well tolerated in humans and that 450 mg/day can represent a safe dose for a 70 kg individual [<xref rid="bib0165" ref-type="bibr">33</xref>]. Resveratrol has low systemic bioavailability and is available in solution form and as a transdermal patch, however, its safety and effectiveness have not been approved by the FDA [<xref rid="bib0170" ref-type="bibr">34</xref>].</p><p id="par0080">Amentoflavone (<bold>12</bold>) a bi-flavonoid isolated from <italic>Selaginella sinensis, Torreya nucifera</italic>, and other medicinal plants has shown <italic>in vitro</italic> potent antiviral activity against respiratory syncytial virus (RSV), with an IC<sub>50</sub> of 5.5 &#x003bc;g/mL [<xref rid="bib0175" ref-type="bibr">35</xref>], as well as significant activity against influenza A and B viruses [<xref rid="bib0180" ref-type="bibr">36</xref>]. Additionally, amentoflavone (<bold>12</bold>) revealed moderate anti-herpes simplex virus HSV-1 and anti-HSV-2 activities with EC<sub>50</sub> values of 17.9 &#x003bc;g/mL (HSV-1) and 48.0 &#x003bc;g/mL (HSV-2), and also described as SARS-CoV 3CL protease inhibitor with an IC<sub>50</sub> of 8.3 &#x003bc;M [<xref rid="bib0185" ref-type="bibr">37</xref>]. This compound has shown high cytotoxicity against MCF-7 and HeLa cancer cell lines [<xref rid="bib0190" ref-type="bibr">38</xref>].</p><p id="par0085">Myricetin (<bold>13</bold>) and scutellarein (<bold>14</bold>) (<xref rid="fig0020" ref-type="fig">Fig. 4</xref>
) are strong inhibitors of SARS-CoV helicase and their effect is mediated through inhibition of ATPase activity. The IC<sub>50</sub> values of myricetin and scutellarein <italic>in vitro</italic> were 2.71 &#x000b1; 0.19 &#x003bc;M and 0.86 &#x000b1; 0.48 &#x003bc;M, respectively [<xref rid="bib0195" ref-type="bibr">39</xref>]. It has been noticed that neither myricetin (<bold>13</bold>) nor scutellarein (<bold>14</bold>) can affect the growth of MCF10A cells at cellular concentrations close to their IC50&#x02032;<sub>s</sub> [<xref rid="bib0200" ref-type="bibr">40</xref>].<fig id="fig0020"><label>Fig. 4</label><caption><p>Phenolic compounds&#x0202f;tested against coronaviruses.</p></caption><alt-text id="at0055">Fig. 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p><p id="par0090">Myricetin <bold>(13)</bold> is a typical plant-derived flavonoid produced fundamentally by individuals from the families <italic>Myricaceae, Anacardiaceae, Polygonaceae, Pinaceae</italic>, and <italic>Primulaceae</italic> and considered as one of the key elements of different beverages [<xref rid="bib0200" ref-type="bibr">40</xref>].</p><p id="par0095">Myricetin <bold>(13)</bold> shows a wide spectrum of activities that incorporate anti-oxidant, anticancer, antidiabetic and anti-inflammatory activities [<xref rid="bib0205" ref-type="bibr">41</xref>]. It shows a few activities that are identified with the central nervous system (CNS) and the compound is suggested to be useful against Parkinson's and Alzheimer's diseases [<xref rid="bib0210" ref-type="bibr">42</xref>]. According to some reports myricetin (<bold>13</bold>) has the capability to modify the immune response or functioning of the immune system [<xref rid="bib0210" ref-type="bibr">42</xref>]. This compound has cytotoxic and apoptosis-promoting effects in prostate cancer (PCa) cells [<xref rid="bib0215" ref-type="bibr">43</xref>].</p><p id="par0100">
<italic>Scutellaria baicalensis</italic> roots have been widely used in traditional Chinese medicine to treat viral infection [<xref rid="bib0220" ref-type="bibr">44</xref>]. <italic>In vitro</italic> and <italic>in vivo</italic> replication of SARS-CoV can be inhibited by the flavonoid baicalin (<bold>15</bold>), which is isolated from <italic>S. baicalensis</italic>. Numerous inhibitory activities were confirmed for baicalin (EC<sub>50</sub> at 48 h is 12.5&#x02013;25 &#x003bc;g/mL and at 72 h is 25&#x02013;50 &#x003bc;g/mL) by virtue of neutralization-based testing of the nine SARS coronavirus isolates [<xref rid="bib0225" ref-type="bibr">45</xref>].</p><p id="par0105">The most potent anti-SARS-CoV-2 3CL<sup>pro</sup> activity was shown by an aglycon of baicalin, baicalein (<bold>16</bold>), with an IC<sub>50</sub> of 0.39 &#x003bc;M. Studies of several analogs have demonstrated the potentiality of additionally four flavonoids as potent inhibitors of SARS-CoV-2 3CL<sup>pro</sup>. These potent inhibitors include scutellarein (<bold>14</bold>), which is largely distributed in genera <italic>Scutellaria</italic> and <italic>Erigerontis</italic>, and shows IC<sub>50</sub> value of 5.8 &#x003bc;M against SARS-CoV-2 3CL<sup>pro</sup>. The other three remaining flavonoid compounds are myricetin (<bold>13</bold>), dihydromyricetin (<bold>17</bold>), and quercetagetin (<bold>18</bold>). They were respectively constituents from <italic>Ampelopsis japonica</italic> (Bailian in Chinese), <italic>Eriocaulon buergerianum</italic> (Gujingcao in Chinese) and <italic>Polygoni avicularis</italic> (Bianxu in Chinese), and possess inhibitory activity against SARS-CoV- 2 3CL<sup>pro</sup> with IC<sub>50</sub> values of 1.20, 1.24, and 2.86 &#x003bc;M [<xref rid="bib0230" ref-type="bibr">46</xref>]. Baicalin has been shown to possess potential cytotoxicity [<xref rid="bib0235" ref-type="bibr">47</xref>].</p><p id="par0110">Tannic acid (<bold>19</bold>) (IC<sub>50</sub> = 3 &#x003bc;M) and 3-isotheaflavin-3-gallate (<bold>20</bold>) (IC<sub>50</sub> = 7 &#x003bc;M) (<xref rid="fig0025" ref-type="fig">Fig. 5</xref>
) were shown to be potent inhibitors of SARS 3CL<sup>pro</sup> by virtue of high-throughput screening of a natural product library (approx. 720 compounds) [<xref rid="bib0240" ref-type="bibr">48</xref>]. These two compounds form part to a group of natural polyphenols found in tea [<xref rid="bib0225" ref-type="bibr">45</xref>]. According to the results obtained, the extracts from Pu-erh tea and black tea were the most potent inhibitors of SARS protease [<xref rid="bib0240" ref-type="bibr">48</xref>]. It was also reported that bovine coronavirus and rotavirus infections could be neutralized by theaflavins extracted from black tea [<xref rid="bib0245" ref-type="bibr">49</xref>] with EC<sub>50</sub> of 34.7 &#x003bc;g/mL. The findings also corroborate the presence of an inactivation activity (<italic>in vitro</italic>) of theaflavin and theaflavin gallate derivatives (<bold>20</bold>) against both rotavirus and coronavirus.<fig id="fig0025"><label>Fig. 5</label><caption><p>Chemical structure of theaflavins extracted from black.</p></caption><alt-text id="at0060">Fig. 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p><p id="par0115">The activity of polyphenols derived from <italic>Broussonetia papyrifera</italic> against 3-chymotrypsin-like and papain-like coronavirus cysteine proteases were discussed by Ji-Young Park et al. [<xref rid="bib0250" ref-type="bibr">50</xref>]. Many polyphenols were discovered to be more potent as inhibitors of papain-like protease (PL<sup>pro</sup>) than those of 3-chymotripsin-like protease (3CL<sup>pro</sup>) [<xref rid="bib0250" ref-type="bibr">50</xref>]. Among these polyphenols, papyriflavonol (<bold>22</bold>) (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>
) was discovered to manifest the most potent inhibitory activity against PL<sup>pro</sup> with an IC<sub>50</sub> value of 3.7 &#x003bc;M while C-5-alkyl group (prenyl)-substituted flavan (<bold>23</bold>) was the most potent against SARS- CoV 3CL<sup>pro</sup> which was proven to be more effective than quercetin derivative (IC<sub>50</sub> = 52.7 &#x003bc;M).<fig id="fig0030"><label>Fig. 6</label><caption><p>Phenolic compounds tested against coronaviruses.</p></caption><alt-text id="at0065">Fig. 6</alt-text><graphic xlink:href="gr6_lrg"/></fig></p><p id="par0120">Recently, it has been suggested by Stevens et al. that polyphenols inhibition of viral proteases associated with viral replication is due to their protein affinity <italic>via</italic> hydrogen bonding [<xref rid="bib0255" ref-type="bibr">51</xref>].</p><p id="par0125">
<italic>Houttuynia cordata Thunb. (Saururaceae)</italic> or HC is a medicinal plant commonly used in folk medicine in a number of Asian countries. It is effective in the treatment of pneumonia, infectious diseases, refractory hemoptysis, and malignant pleural effusion [<xref rid="bib0260" ref-type="bibr">52</xref>]. It was the main herbal component of heat-removing and detoxifying formula during the severe acute respiratory syndrome (SARS) outbreak in 2002&#x02013;2003 [<xref rid="bib0265" ref-type="bibr">53</xref>]. Considerable inhibitory effects were demonstrated <italic>in vitro</italic> and <italic>in vivo</italic> by HC water extract on both SARS-CoV 3C-like protease (3CL<sup>pro</sup>) and RNA-dependent RNA polymerase [<xref rid="bib0270" ref-type="bibr">54</xref>], where HC extract was discovered to be an effective inhibitor of [<italic>&#x003b1;</italic>-<sup>32</sup>P] UTP incorporation at 50 &#x003bc;g/mL. Interestingly, oral acute toxicity analysis demonstrated that HC was non-toxic to laboratory animals after an oral administration at 16 g/kg.</p><p id="par0130">The inhibitory activities of chalcones and coumarins isolated from the edible <italic>Angelica keiskei</italic> against SARS-CoV proteases (3CL<sup>pro</sup> and PL<sup>pro</sup>) were determined (cell-free/based) [<xref rid="bib0275" ref-type="bibr">55</xref>]. Xanthoangelol E (<bold>24</bold>) (<xref rid="fig0030" ref-type="fig">Fig. 6</xref>), exhibited the most inhibitory activity against 3CL<sup>pro</sup> and PL<sup>pro</sup> with IC<sub>50</sub> values of 11.4 and 1.2 &#x003bc;M [<xref rid="bib0280" ref-type="bibr">56</xref>]. Data suggested that chalcones exhibited competitive inhibition to the SARS-CoV 3 CL<sup>pro</sup> and noncompetitive inhibition to the SARS-CoV PL<sup>pro</sup>.</p></sec><sec id="sec0030"><label>1.2.3</label><title>Terpenoids</title><p id="par0135">Terpenoids represent diverse class of molecules that provide a wealth of opportunities to address many human health and societal issues. <italic>Euphorbia neriifolia L.</italic> is an herb local to Southeast Asia. From leaves of <italic>E. neriifolia,</italic> 23 compounds were isolated, including 22 triterpenoids and one flavonoid glycoside [<xref rid="bib0285" ref-type="bibr">57</xref>]. The antiviral activity of all the isolated compounds was evaluated. The assay results indicated the highly influence of the antiviral activity with small differences in the structural features of the tested compounds. Among the friedelane derivatives tested, two epimers, 3<italic>&#x003b2;</italic>- friedelanol and 3<italic>&#x003b1;</italic>-friedelanol, with difference orientation at C-3 that affected dramatically their antiviral activity while epitaraxerol (<bold>25</bold>) (<xref rid="fig0035" ref-type="fig">Fig. 7</xref>
), a taraxerane derivative, was the most active derivative [<xref rid="bib0285" ref-type="bibr">57</xref>].<fig id="fig0035"><label>Fig. 7</label><caption><p>Chemical structure of triterpenoids and Savinin.</p></caption><alt-text id="at0070">Fig. 7</alt-text><graphic xlink:href="gr7_lrg"/></fig></p><p id="par0140">Glycyrrhizin (<bold>26</bold>) (<xref rid="fig0035" ref-type="fig">Fig. 7</xref>), the active component of <italic>liquorice roots</italic>, has been reported to possess moderate antiviral activity against SARS-CoV <italic>in vitro</italic> with an EC<sub>50</sub> of 300 g/mL [<xref rid="bib0290" ref-type="bibr">58</xref>], however its full mechanism is unclear. Glycyrrhizin affects cellular signaling pathways such as protein kinase C; casein kinase II; and transcription factors such as activator protein 1 and nuclear factor kB (NF-&#x003ba;B).</p><p id="par0145">Saikosaponins isolated from medicinal plants such as <italic>Bupleurum spp.</italic>, <italic>Heteromorpha spp.</italic>, and <italic>Scrophularia scorodonia</italic> have been reported to produce various biological activities including antihepatitic, antinephritic, antihepatomic, anti-inflammatory, immunomodulatory, and antibacterial effects [<xref rid="bib0295" ref-type="bibr">[59]</xref>, <xref rid="bib0300" ref-type="bibr">[60]</xref>, <xref rid="bib0305" ref-type="bibr">[61]</xref>]. The cytotoxicity of saikosaponins A, B2, C, D and actinomycin D on MRC-5 cells using the XTT assay indicated no cytotoxic effect on the cells at concentrations of 2.5 &#x003bc;M/L. Saikosaponins (A, B2, C and D) were examined for their anticoronaviral activity, where saikosaponin B2 (<bold>27</bold>) (<xref rid="fig0035" ref-type="fig">Fig. 7</xref>) has potent anticoronaviral activity [<xref rid="bib0310" ref-type="bibr">62</xref>]. The percentage viral inhibition for 0.25, 2.5, and 25 &#x003bc;M/L saikosaponin B2 was 35.7 &#x000b1; 0.7, 63.0 &#x000b1; 0.8, and 100.0 &#x000b1; 0.2 %, respectively. The mechanistic studies show that saikosaponin B2 inhibits HCoV-229E infection in a dose- and time-dependent manner, block viral penetration into cells, and interfere with the early stage of viral replication, such as virus absorption and penetration.</p><p id="par0150">In another study, 221 phytocompounds were evaluated for their activity against severe acute respiratory syndrome associated coronavirus (SARS-CoV) using a cell-based assay measuring SARS-CoV-induced cytopathogenic effect on Vero E6 cells. Twenty tested compounds exhibited significant levels of anti-SARS-CoV activity at 10 &#x003bc;M with no cytotoxicity against Vero E6 cells. Due to its pivotal role in the SARS-CoV life cycle, the 3CL protease is a key target for discovery of anti-SARS- CoV agents [<xref rid="bib0315" ref-type="bibr">63</xref>]. The inhibitory effects of compounds on SARS-CoV 3CL protease activity were investigated. Only betulinic acid (<bold>28</bold>) (IC<sub>50</sub> = 10 &#x003bc;M, <italic>K<sub>i</sub></italic> = 8.2 &#x000b1; 0.7 &#x003bc;M) and savinin (<bold>29</bold>) (IC<sub>50</sub> = 25 &#x003bc;M, <italic>Ki</italic> = 9.1 &#x000b1; 2.4 &#x003bc;M) (<xref rid="fig0035" ref-type="fig">Fig. 7</xref>) exhibited significant inhibition on 3CL protease. The mechanism of action of betulinic acid and savinin on 3CL protease was shown to be competitive inhibition <italic>via</italic> molecular docking [<xref rid="bib0315" ref-type="bibr">63</xref>,<xref rid="bib0320" ref-type="bibr">64</xref>].</p></sec><sec id="sec0035"><label>1.2.4</label><title>Fatty acids and polyketides- diarylheptanoids</title><p id="par0155">
<italic>Alnus japonica</italic> and its constituents exhibit various biological properties, including anti-inflammatory, anticancer, and anti-influenza activities. The ethanol extract of the stem bark of <italic>A. japonica</italic> exhibited PL<sup>pro</sup> inhibitory activity. Nine diarylheptanoids were identified; platyphyllenone, hirsutenone (<bold>30</bold>), platyphyllone, platyphyllonol-5-xylopyranoside, hirsutanonol, oregonin, rubranol, rubranoside B (<bold>31</bold>), and rubranoside (<bold>32</bold>) (<xref rid="fig0040" ref-type="fig">Fig. 8</xref>
) [<xref rid="bib0325" ref-type="bibr">65</xref>]. The isolated compounds were tested against SARS-CoV PL<sup>pro</sup> using a continuous fluorometric assay, where six diarylheptanoids showed a dose-dependent inhibitory effect against the PL<sup>pro</sup>. Compounds <bold>30</bold> and <bold>31</bold> exhibited modest activity, with IC<sub>50</sub> values of 8.0 and 9.1 &#x003bc;M. These compounds also were tested using recombinant 3CL<sup>pro</sup> expressed <italic>in vitro</italic>, where compound <bold>32</bold> exhibited stronger 3CL<sup>pro</sup> inhibition than the other derivatives with IC<sub>50</sub> = 36.2 <italic>&#x003bc;</italic>M.<fig id="fig0040"><label>Fig. 8</label><caption><p>Diarylhepatanoids from <italic>Alnus japonica (Betulaceae).</italic></p></caption><alt-text id="at0075">Fig. 8</alt-text><graphic xlink:href="gr8_lrg"/></fig></p><p id="par0160">The diarylheptanoids were found to be reversible inhibitors, where an increase in concentration rapidly reduced enzyme activity [<xref rid="bib0325" ref-type="bibr">65</xref>]. Structural-activity relationship (SAR) of diarylheptanoids established that <italic>&#x003b1;</italic>, <italic>&#x003b2;</italic>-unsaturated carbonyl and catechol groups may play a pivotal role in SARS-CoV PL<sup>pro</sup> inhibition by interacting with the PL<sup>pro</sup> nucleophiles [<xref rid="bib0325" ref-type="bibr">65</xref>]. The mechanism of inhibition of cysteine protease may involve the formation of a covalent bond between the carbonyl group located at the warhead of the inhibitor and the cysteine active site residue in the enzyme.</p><p id="par0165">A number of experiments aimed at the evaluation of the inhibitory activity and the effects of Chinese medicinal herbs on the S protein and ACE2 interaction have been carried out by T.-Y. Ho et al. [<xref rid="bib0330" ref-type="bibr">66</xref>]. The herbs were divided by the team into 32 families in order to compare the levels of inhibition through taxonomic characterization. Up to 60&#x02013;90 % of the binding of S protein to Angiotensin-converting enzyme 2 (ACE2) at 1 &#x003bc;g was blocked by six herb families, including <italic>Nelumbonaceae, Labiatae, Magnoliaceae, Oleaceae, Lauraceae,</italic> and <italic>Polygonaceae</italic>. Among the given families, the highest inhibitory effect on the S protein and ACE2 interaction was demonstrated by <italic>Polygonaceae</italic>, with t inhibitory percentage of 86.33 &#x000b1; 4.55 %, where <italic>Radix et Rhizoma Rheim, Radix Polygoni multiflora</italic>, and <italic>Caulis Polygoni multiflori</italic> pertain to <italic>Polygonaceae</italic> [<xref rid="bib0335" ref-type="bibr">67</xref>]. Emodin, the major components of the genus <italic>Rheum</italic> and <italic>Polygonum</italic>, is the likely active constituent responsible for blocking both the binding of SARS-CoV S protein to ACE2. Emodin (<bold>33</bold>) (<xref rid="fig0045" ref-type="fig">Fig. 9</xref>
) blocked the binding of S protein to ACE2 in a dose-dependent manner. The IC<sub>50</sub> value of emodin is 200 &#x003bc;M. Emodin is an anthraquinone compound consists of three cyclic rings. The anti-psychotic drug promazine (<bold>34</bold>) (<xref rid="fig0045" ref-type="fig">Fig. 9</xref>), which has been shown to exhibit the significant effect in inhibiting the replication of SARS-CoV [<xref rid="bib0340" ref-type="bibr">68</xref>], shared a similar structure with emodin. As compared to emodin, promazine exhibited the highest inhibition. However, the differences between emodin and promazine were not significant.<fig id="fig0045"><label>Fig. 9</label><caption><p>Chemical structure of emodin and promazine.</p></caption><alt-text id="at0080">Fig. 9</alt-text><graphic xlink:href="gr9_lrg"/></fig></p></sec><sec id="sec0040"><label>1.2.5</label><title>Current trends and clinical trials</title><p id="par0170">Many anti-immune treatments, investigational clinical trials using repurposed drugs for evaluation of direct antiviral activity have already been launched, including multiple antiviral and antimalarial medicines [<xref rid="bib0340" ref-type="bibr">68</xref>]. A great effort has been addressed towards sharing information on biomolecular simulation data to reveal models of how the coronavirus could potentially infect human, as well as how to prevent and/or treat COVID-19 [<xref rid="bib0345" ref-type="bibr">69</xref>].</p><p id="par0175">Recently, Riva et al., reported a high-throughput analysis of approximately 12,000 known drugs evaluated for their activity against SARS-CoV-2 replication which afforded 30 known drugs capable to inhibit viral SARS-CoV-2 replication [<xref rid="bib0345" ref-type="bibr">69</xref>]. Six drugs were further characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. The mechanism of those drugs includes the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1 antagonist MLN-3897 [<xref rid="bib0350" ref-type="bibr">70</xref>].</p><p id="par0180">There are several ongoing clinical trials using repurposed clinical-stage or approved drugs such as remdesivir, favipiravir, lopinavir/ritonavir, hydroxychloroquine, and natural or semisynthetic products like quercetin [<xref rid="bib0355" ref-type="bibr">71</xref>,<xref rid="bib0360" ref-type="bibr">72</xref>], colchicine [<xref rid="bib0365" ref-type="bibr">73</xref>], tetrandrine [<xref rid="bib0370" ref-type="bibr">74</xref>], desferrioxamine B [<xref rid="bib0375" ref-type="bibr">75</xref>], azithromycin [<xref rid="bib0380" ref-type="bibr">[76]</xref>, <xref rid="bib0385" ref-type="bibr">[77]</xref>, <xref rid="bib0390" ref-type="bibr">[78]</xref>] (<xref rid="fig0050" ref-type="fig">Fig. 10</xref>
) are under investigation for treating COVID-19 patients, as well as several vaccines are in fast phases of clinical trials. Selected examples of natural products which are in current clinical trials to treat COVID-19 are shown below.<fig id="fig0050"><label>Fig. 10</label><caption><p>Natural and semisynthetic compounds that are under ongoing clinical trials.</p></caption><alt-text id="at0085">Fig. 10</alt-text><graphic xlink:href="gr10_lrg"/></fig></p><p id="par0185">Desferrioxamine B (Desferal&#x000ae;) is produced by <italic>Streptomyces pilosus</italic> and the only siderophore currently marketed (DB00746). It is produced by the fermentation of <italic>S. pilosus</italic> and is used therapeutically in patients with iron and aluminum overload [<xref rid="bib0395" ref-type="bibr">79</xref>]. Desferrioxamine B is also known for its antiproliferative activity against leukemia and neuroblastoma cells <italic>in vitro</italic> and <italic>in vivo</italic> and in current clinical trials for its antitumor activity [<xref rid="bib0400" ref-type="bibr">80</xref>]. Replication of human immunodeficiency virus type 1 (HIV-1) can be influenced by iron, hence, decreasing the availability of iron may inhibit HIV-1 replication, where deferoxamine is capable of forming catalytically inactive iron-chelator complexes [<xref rid="bib0405" ref-type="bibr">81</xref>].</p><p id="par0190">Quercetin is reported to be effective on treatment and prophylaxis of other SARS like coronavirus infections, as a strong antioxidant and scavenger flavonoid without any serious reported adverse effects. This in turn motivates investigators to consider quercetin as an effective lead on both prophylaxis and treatment of COVID-19 cases [<xref rid="bib0410" ref-type="bibr">82</xref>].</p><p id="par0195">Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamid, Avigan&#x000ae;) is an antiviral drug that selectively inhibited the RdRP of influenza virus [<xref rid="bib0415" ref-type="bibr">83</xref>]. It showed specific activity against all three influenza A, B, and C [<xref rid="bib0420" ref-type="bibr">84</xref>,<xref rid="bib0425" ref-type="bibr">85</xref>]. The primary mechanism of action of favipiravir against the influenza virus was through specific inhibition to vRNA polymerase [<xref rid="bib0430" ref-type="bibr">86</xref>]. Favipiravir functions as a purine homologue, where vRNA polymerase mistakenly recognizes favipiravir-RTP as a purine nucleotide resulted in inhibition of viral RNA synthesis [<xref rid="bib0430" ref-type="bibr">86</xref>].</p><p id="par0200">Colchicine (Colcrys&#x000ae;) is an alkaloid isolated from the plant <italic>Colchicum autumnale</italic>. It is a drug used to treat gout and Beh&#x000e7;et's disease with narrow therapeutic-toxicity window and a marked variability between individuals in drug disposition [<xref rid="bib0435" ref-type="bibr">87</xref>]. Colchicine binds in an equimolar and poorly reversible manner to soluble nonpolymerized tubulin with high activation energy, forming a tubulin-colchicine complex [<xref rid="bib0440" ref-type="bibr">88</xref>].</p><p id="par0205">It appears through this short review that natural products with the unique pharmacophores and high safety margin will present key element in dealing with the pandemic 2019-nCoV.</p></sec></sec></sec><sec id="sec0045"><label>2</label><title>Conclusions</title><p id="par0210">There is an urgent and critical need to identify novel medical countermeasures both for prophylactic and treatment use. Since the production of a vaccine could take 12&#x02013;18 months, and de novo development of therapies usually requires 10&#x02013;17 years, repositioning clinically evaluated drugs represents one of the most practicable strategies for the rapid identification and deployment of treatments for emerging infectious diseases such as COVID-19 [<xref rid="bib0325" ref-type="bibr">65</xref>].</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="par0215">The authors declare no conflict of interest.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="book" id="sbref0005"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title>Coronaviruses: an overview of their replication and pathogenesis</chapter-title><person-group person-group-type="editor"><name><surname>Maier</surname><given-names>H.</given-names></name><name><surname>Bickerton</surname><given-names>E.</given-names></name><name><surname>Britton</surname><given-names>P.</given-names></name></person-group><source>Coronaviruses. Methods in Molecular Biology</source><year>2015</year><fpage>1282</fpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="book" id="sbref0010"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>S.</given-names></name></person-group><chapter-title>Family Coronaviridae. Viruses</chapter-title><year>2017</year><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-803109-4.00017-9</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Myint</surname><given-names>S.H.</given-names></name></person-group><article-title>Human coronaviruses: a brief review</article-title><source>Rev. Med. Virol.</source><volume>4</volume><issue>1</issue><year>1994</year><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/rmv.1980040108</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>P.H.</given-names></name></person-group><article-title>Characterization and inhibition of SARS-coronavirus main protease</article-title><source>Curr. Top. Med. Chem.</source><volume>6</volume><issue>4</issue><year>2006</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.2174/156802606776287090</pub-id><pub-id pub-id-type="pmid">16611148</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Rachel</surname><given-names>L.G.</given-names></name><name><surname>Ralph</surname><given-names>S.B.</given-names></name></person-group><article-title>Recombination, reservoirs, and the modular spike, mechanisms of coronavirus cross-species transmission</article-title><source>J. Virol.</source><volume>84</volume><issue>7</issue><year>2010</year><fpage>3134</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1128/jvi.01394-09</pub-id><pub-id pub-id-type="pmid">19906932</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>Y.</given-names></name></person-group><article-title>COVID-19: what has been learned and to be learned about the novel coronavirus disease</article-title><source>Int. J. Biol. Sci.</source><volume>16</volume><issue>10</issue><year>2020</year><fpage>1753</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.7150/ijbs.45134</pub-id><pub-id pub-id-type="pmid">32226295</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>van der Hoek</surname><given-names>L.</given-names></name></person-group><article-title>Identification of a new human coronavirus</article-title><source>Nat. Med.</source><volume>10</volume><year>2004</year><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1038/nm1024</pub-id><pub-id pub-id-type="pmid">15034574</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name></person-group><article-title>Return of the coronavirus: 2019-nCoV return of the coronavirus: 2019-nCoV</article-title><source>Viruses</source><volume>12</volume><year>2020</year><fpage>135</fpage><pub-id pub-id-type="doi">10.3390/v12020135</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>14</volume><issue>8</issue><year>2016</year><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><mixed-citation publication-type="other" id="oref0050">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or#:&#x0223c;:text=FDA%20cautions%20against%20use%20of%20hydroxychloroquine%20or%20chloroquine,treat%20hospitalized%20patients%20with%20COVID-19%20is%20now%20available, accessed on 09/27/2020.</mixed-citation></ref><ref id="bib0055"><label>11</label><mixed-citation publication-type="other" id="oref0055"><ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/us-map" id="intr0005">https://coronavirus.jhu.edu/us-map</ext-link>, accessed on 07/13/2020.</mixed-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Pruijssers</surname><given-names>A.J.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name></person-group><article-title>Nucleoside analogues for the treatment of coronavirus infections</article-title><source>Curr. Opin. Virol.</source><volume>35</volume><year>2019</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.04.002</pub-id><pub-id pub-id-type="pmid">31125806</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Osterhaus</surname><given-names>D.M.</given-names></name></person-group><article-title>Coronaviruses and their therapy</article-title><source>Antiviral Res.</source><volume>71</volume><year>2006</year><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.05.019</pub-id><pub-id pub-id-type="pmid">16837072</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat. Rev., Drug Discover</source><volume>19</volume><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00016-0</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W.</given-names></name></person-group><article-title>Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by Remdesivir</article-title><source>Science</source><volume>368</volume><issue>6498</issue><year>2020</year><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1126/science.abc1560</pub-id><pub-id pub-id-type="pmid">32358203</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Yeming</surname><given-names>W.</given-names></name></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-31029</pub-id><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.E.</given-names></name></person-group><article-title>Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells</article-title><source>Biomolecules</source><volume>9</volume><issue>11</issue><year>2019</year><fpage>696</fpage><pub-id pub-id-type="doi">10.3390/biom9110696</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>X.L.</given-names></name></person-group><article-title>Bisbenzylisoquinoline alkaloids of lotus (<italic>Nelumbo nucifera Gaertn.</italic>) seed embryo inhibit lipopolysaccharide-induced macrophage activation via suppression of Ca<sup>2+</sup>-CaM/CaMKII pathway</article-title><source>Food Agric. Immunol.</source><volume>30</volume><issue>1</issue><year>2019</year><fpage>878</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1080/09540105.2019.1638889</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Traditional Chinese medicine in the treatment of patients infected with 2019-New coronavirus (SARS-CoV-2): a review and perspective</article-title><source>Int. J. Biol. Sci.</source><volume>16</volume><issue>10</issue><year>2020</year><fpage>1708</fpage><lpage>1717</lpage><pub-id pub-id-type="doi">10.7150/ijbs.45538</pub-id><pub-id pub-id-type="pmid">32226288</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>The status of Chinese medicine in reversing multi-drug resistance of hepatocellular carcinoma</article-title><source>Chin. -Ger. J. Clin. Oncol.</source><volume>10</volume><year>2011</year><fpage>541</fpage><pub-id pub-id-type="doi">10.1007/s10330-011-0828-1</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Yi-Tsau</given-names></name><name><surname>Hong</surname><given-names>Chuang-Ye</given-names></name></person-group><article-title>Tetrandrine</article-title><source>Cardiovasc. Drug Rev.</source><volume>16</volume><issue>1</issue><year>1998</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3466.1998.tb00341.x</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Ding</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name></person-group><article-title>Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells</article-title><source>Int. J. Oncol.</source><volume>46</volume><year>2015</year><fpage>2355</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.3892/ijo.2015.2959</pub-id><pub-id pub-id-type="pmid">25872479</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name></person-group><article-title>W. Treatment of SARS with human interferons</article-title><source>Lancet</source><volume>362</volume><year>2003</year><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13973-6</pub-id><pub-id pub-id-type="pmid">12892961</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Kretzing</surname><given-names>S.</given-names></name></person-group><article-title>Dose-dependent emetic effects of the <italic>Amaryllidaceous</italic> alkaloid lycorine in beagle dogs</article-title><source>Toxicon</source><volume>57</volume><year>2011</year><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.10.012</pub-id><pub-id pub-id-type="pmid">21055413</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.Y.</given-names></name></person-group><article-title>Identification of natural compounds with antiviral activities against SARS-associated coronavirus</article-title><source>Antiviral Res.</source><volume>67</volume><year>2005</year><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.02.007</pub-id><pub-id pub-id-type="pmid">15885816</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Ch.W.</given-names></name></person-group><article-title>Anti-SARS coronavirus 3C-like protease effects of <italic>Isatis indigotica</italic> root and plant-derived phenolic compounds</article-title><source>Antiviral Res.</source><volume>68</volume><year>2005</year><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2005.07.002</pub-id><pub-id pub-id-type="pmid">16115693</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Mazumder</surname><given-names>A.</given-names></name></person-group><article-title>Sinigrin and its therapeutic benefits</article-title><source>Molecules</source><volume>21</volume><issue>4</issue><year>2016</year><fpage>416</fpage><pub-id pub-id-type="doi">10.3390/molecules21040416</pub-id><pub-id pub-id-type="pmid">27043505</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Chafekar</surname><given-names>A.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name></person-group><article-title>MERS-CoV: understanding the latest human coronavirus threat</article-title><source>Viruses</source><volume>10</volume><issue>2</issue><year>2018</year><fpage>93</fpage><pub-id pub-id-type="doi">10.3390/v10020093</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Docherty</surname><given-names>J.J.</given-names></name></person-group><article-title>Resveratrol inhibition of herpes simplex virus replication</article-title><source>Antiviral Res.</source><volume>43</volume><issue>3</issue><year>1999</year><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/s0166-3542(99)00042-x</pub-id><pub-id pub-id-type="pmid">10551373</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>A.R.</given-names></name></person-group><article-title>Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions</article-title><source>Curr. Med. Chem.</source><volume>19</volume><year>2012</year><fpage>1663</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.2174/092986712799945085</pub-id><pub-id pub-id-type="pmid">22257059</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Fr&#x000e9;mont</surname><given-names>L.</given-names></name></person-group><article-title>Biological effects of resveratrol</article-title><source>Life Sci.</source><volume>66</volume><issue>8</issue><year>2000</year><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(99)00410-5</pub-id><pub-id pub-id-type="pmid">10680575</pub-id></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Henning</surname><given-names>S.M.</given-names></name></person-group><article-title>Variability in the antioxidant activity of dietary supplements from pomegranate, milk thistle, green tea, grape seed, goji, and acai: effects of <italic>in vitro</italic> digestion</article-title><source>J. Agric. Food Chem.</source><volume>62</volume><year>2014</year><fpage>4313</fpage><lpage>4332</lpage><pub-id pub-id-type="doi">10.1021/jf500106r</pub-id><pub-id pub-id-type="pmid">24745654</pub-id></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>L.A.</given-names></name></person-group><article-title>Review of the biology and ecology of three invasive perennials in New York state: japanese knotweed (<italic>Polygonum cuspidatum</italic>), mugwort (<italic>Artemisia vulgaris</italic>) and pale swallow-wort (<italic>Vincetoxicum rossicum</italic>)</article-title><source>Plant Soil</source><volume>277</volume><year>2005</year><fpage>53</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s11104-005-3102-x</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Timmers</surname><given-names>S.</given-names></name></person-group><article-title>Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans</article-title><source>Cell Metab.</source><volume>14</volume><year>2011</year><fpage>612</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2011.10.002</pub-id><pub-id pub-id-type="pmid">22055504</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y.M.</given-names></name></person-group><article-title>Antiviral activities of biflavonoids</article-title><source>Planta Med.</source><volume>65</volume><year>1999</year><fpage>120</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1055/s-1999-13971</pub-id><pub-id pub-id-type="pmid">10193201</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Shuang-Cheng</given-names></name></person-group><article-title>Antiviral Amentoflavone from <italic>Selaginella sinensis</italic></article-title><source>Biol. Pharm. Bull.</source><volume>24</volume><issue>3</issue><year>2001</year><fpage>311</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1248/bpb.24.311</pub-id><pub-id pub-id-type="pmid">11256492</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>Y.B.</given-names></name></person-group><article-title>Biflavonoids from T<italic>orreya nucifera</italic> displaying SARS&#x02010;CoV 3CL (pro) inhibition</article-title><source>Bioorg. Med Chem</source><volume>18</volume><year>2010</year><fpage>7940</fpage><lpage>7947</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.09.035</pub-id><pub-id pub-id-type="pmid">20934345</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Eunjung</given-names></name></person-group><article-title>Cytotoxic activities of amentoflavone against human breast and cervical cancers are mediated by increasing of PTEN expression levels due to peroxisome proliferator-activated receptor &#x003b3; activation</article-title><source>Bull. Korean Chem. Soc.</source><volume>33</volume><issue>7</issue><year>2012</year><fpage>2219</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.5012/bkcs.2012.33.7.2219</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.S.</given-names></name></person-group><article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>22</volume><year>2012</year><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id><pub-id pub-id-type="pmid">22578462</pub-id></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Semwal</surname><given-names>D.</given-names></name></person-group><article-title>Myricetin: a dietary molecule with diverse biological activities</article-title><source>Nutrients</source><volume>8</volume><issue>2</issue><year>2016</year><fpage>90</fpage><pub-id pub-id-type="doi">10.3390/nu8020090</pub-id><pub-id pub-id-type="pmid">26891321</pub-id></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Chan</surname></name></person-group><article-title>Interactions between traditional Chinese medicines and Western therapeutics</article-title><source>Curr. Opin. Drug Discov. Devel.</source><volume>13</volume><issue>1</issue><year>2010</year><fpage>50</fpage><lpage>65</lpage></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease: cell - specific pathology isolates the hippocampal formation</article-title><source>Science</source><volume>225</volume><year>1984</year><fpage>1168</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1126/science.6474172</pub-id><pub-id pub-id-type="pmid">6474172</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>C.</given-names></name></person-group><article-title>The natural compound myricetin effectively represses the malignant progression of prostate Cancer by inhibiting PIM1 and disrupting the PIM1/CXCR4 interaction</article-title><source>Cell. Physiol. Biochem.</source><volume>48</volume><year>2018</year><fpage>1230</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1159/000492009</pub-id><pub-id pub-id-type="pmid">30045021</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>Zh</given-names></name></person-group><article-title>Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants</article-title><source>Science bulletin</source><volume>61</volume><issue>18</issue><year>2016</year><fpage>1391</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1007/s11434-016-1136-5</pub-id><pub-id pub-id-type="pmid">27730005</pub-id></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name></person-group><article-title>In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds</article-title><source>J. clin. Virol. off. Pub. Pan American Soc. Clin. Virol.</source><volume>31</volume><issue>1</issue><year>2004</year><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.03.003</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="book" id="sbref0230"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Hongbo</given-names></name></person-group><chapter-title>Scutellaria Baicalensis Extract and Baicalein Inhibit Replication of SARS-CoV-2 and its 3C-like Protease in Vitro</chapter-title><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.10.035824</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Invest. New Drugs</source><volume>29</volume><year>2011</year><fpage>637</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9402-x</pub-id><pub-id pub-id-type="pmid">20204673</pub-id></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.N.</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3C-like protease activity by Theaflavin-3,3-digallate (TF3)</article-title><source>Evid. Based Complement. Altern. Med.</source><volume>2</volume><year>2005</year><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>K.J.</given-names></name></person-group><article-title>An <italic>in vitro</italic> study of theaflavins extracted from black tea to neutralize bovine rotavirus and bovine coronavirus infections</article-title><source>Vet. Microbiol.</source><volume>63</volume><year>1998</year><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(98)00242-9</pub-id><pub-id pub-id-type="pmid">9850995</pub-id></element-citation></ref><ref id="bib0250"><label>50</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Evaluation of polyphenols from <italic>Broussonetia papyrifera</italic> as coronavirus protease inhibitors</article-title><source>J. Enzyme Inhib. Med. Chem.</source><volume>32</volume><issue>1</issue><year>2017</year><fpage>504</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1080/14756366.2016.1265519</pub-id><pub-id pub-id-type="pmid">28112000</pub-id></element-citation></ref><ref id="bib0255"><label>51</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Paraiso</surname><given-names>I.L.</given-names></name></person-group><article-title>Potential use of polyphenols in the battle against COVID-19</article-title><source>Curr. Opin. Food Sci.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cofs.2020.08.004</pub-id></element-citation></ref><ref id="bib0260"><label>52</label><element-citation publication-type="journal" id="sbref0260"><article-title>Anon herba Houttuynia</article-title><source>Modern Study Trad. Chinese Med.</source><volume>3</volume><year>1997</year><fpage>2983</fpage><lpage>3003</lpage></element-citation></ref><ref id="bib0265"><label>53</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Thiel</surname></name></person-group><article-title>Mechanisms and enzymes involved in SARS coronavirus genome expression</article-title><source>J. Gen. Virol.</source><volume>84</volume><year>2003</year><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1099/vir.0.19424-0</pub-id><pub-id pub-id-type="pmid">12917450</pub-id></element-citation></ref><ref id="bib0270"><label>54</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>K.M.</given-names></name></person-group><article-title>Immunomodulatory and anti&#x02010;SARS activities of Houttuy<italic>nia cordata</italic></article-title><source>J. Ethnopharmacol.</source><volume>118</volume><year>2008</year><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2008.03.018</pub-id><pub-id pub-id-type="pmid">18479853</pub-id></element-citation></ref><ref id="bib0275"><label>55</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases</article-title><source>Bioorg. Med. Chem.</source><volume>20</volume><year>2012</year><fpage>5928</fpage><lpage>5935</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.07.038</pub-id><pub-id pub-id-type="pmid">22884354</pub-id></element-citation></ref><ref id="bib0280"><label>56</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Chalcones isolated from <italic>Angelica keiskei</italic> inhibit cysteine proteases of SARS-CoV</article-title><source>J. Enzyme Inhib. Med. Chem.</source><volume>31</volume><issue>1</issue><year>2016</year><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3109/14756366.2014.1003215</pub-id></element-citation></ref><ref id="bib0285"><label>57</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>F.R.</given-names></name></person-group><article-title>Anti-Human Coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorb<italic>ia neriifolia</italic></article-title><source>Nat. Prod. Commun.</source><volume>7</volume><year>2012</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1177/1934578X1200701103</pub-id><pub-id pub-id-type="pmid">22428227</pub-id></element-citation></ref><ref id="bib0290"><label>58</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name></person-group><article-title>Glycyrrhizin, an active component of <italic>liquorice roots</italic>, and replication of SARS-associated coronavirus</article-title><source>Lancet</source><volume>361</volume><year>2003</year><fpage>2045</fpage><lpage>2059</lpage><pub-id pub-id-type="pmid">12814717</pub-id></element-citation></ref><ref id="bib0295"><label>59</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Guinea</surname><given-names>M.C.</given-names></name></person-group><article-title>Biologically active triterpene saponins from Bupleur<italic>um fruticosum</italic></article-title><source>Planta Med.</source><volume>60</volume><year>1994</year><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1055/s-2006-959442</pub-id><pub-id pub-id-type="pmid">8202567</pub-id></element-citation></ref><ref id="bib0300"><label>60</label><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Recio</surname><given-names>M.C.</given-names></name></person-group><article-title>Anti-in&#x0fb02;ammatory activity of Saikosaponins from Heterom<italic>orpha trifoliate</italic></article-title><source>J. Nat. Prod.</source><volume>58</volume><year>1995</year><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1021/np50115a023</pub-id><pub-id pub-id-type="pmid">7760072</pub-id></element-citation></ref><ref id="bib0305"><label>61</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Bermejo Benito</surname><given-names>P.</given-names></name></person-group><article-title><italic>In vivo</italic> and <italic>in vitro</italic> anti-in&#x0fb02;ammatory activity of Saikosaponins</article-title><source>Life Sci.</source><volume>63</volume><year>1998</year><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(98)00376-2</pub-id><pub-id pub-id-type="pmid">9763210</pub-id></element-citation></ref><ref id="bib0310"><label>62</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>P.W.</given-names></name></person-group><article-title>Antiviral effects of Saikosaponins on human coronavirus 229E in vitr<italic>o</italic></article-title><source>Clin. Exp. Pharmacol. Physiol.</source><volume>33</volume><year>2006</year><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2006.04415.x</pub-id><pub-id pub-id-type="pmid">16789928</pub-id></element-citation></ref><ref id="bib0315"><label>63</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Wen</surname></name></person-group><article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus</article-title><source>J. Med. Chem.</source><volume>50</volume><year>2007</year><fpage>4087</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1021/jm070295s</pub-id><pub-id pub-id-type="pmid">17663539</pub-id></element-citation></ref><ref id="bib0320"><label>64</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor</article-title><source>PNAS</source><volume>100</volume><issue>23</issue><year>2003</year><fpage>13190</fpage><lpage>13195</lpage><pub-id pub-id-type="doi">10.1073/pnas.1835675100</pub-id><pub-id pub-id-type="pmid">14585926</pub-id></element-citation></ref><ref id="bib0325"><label>65</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name></person-group><article-title>Diarylheptanoids from <italic>Alnus japonica</italic> inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol. Pharm. Bull.</source><volume>35</volume><issue>11</issue><year>2012</year><fpage>2036</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1248/bpb.b12-00623</pub-id><pub-id pub-id-type="pmid">22971649</pub-id></element-citation></ref><ref id="bib0330"><label>66</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.Y.</given-names></name></person-group><article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction</article-title><source>Antiviral Res.</source><volume>74</volume><year>2007</year><fpage>92</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id><pub-id pub-id-type="pmid">16730806</pub-id></element-citation></ref><ref id="bib0335"><label>67</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.W.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs</article-title><source>Bioorg. Med. Chem.</source><volume>12</volume><issue>10</issue><year>2004</year><fpage>2517</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2004.03.035</pub-id><pub-id pub-id-type="pmid">15110833</pub-id></element-citation></ref><ref id="bib0340"><label>68</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Kiplin</surname><given-names>G.</given-names></name></person-group><article-title>Rapid repurposing of drugs for COVID-19</article-title><source>Science</source><volume>368</volume><issue>6493</issue><year>2020</year><fpage>829</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1126/science.abb9332</pub-id><pub-id pub-id-type="pmid">32385101</pub-id></element-citation></ref><ref id="bib0345"><label>69</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Riva</surname><given-names>Laura</given-names></name></person-group><article-title>A large-scale drug repositioning survey for SARS-CoV-2</article-title><source>Antivirals</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.16.044016</pub-id></element-citation></ref><ref id="bib0350"><label>70</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Amaro</surname><given-names>Rommie E.</given-names></name><name><surname>Adrian Mulholland</surname><given-names>J.</given-names></name></person-group><article-title>A community letter regarding sharing biomolecular simulation data for COVID-19</article-title><source>J. Chem. Inf. Model.</source><volume>60</volume><issue>6</issue><year>2020</year><fpage>2653</fpage><lpage>2656</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00319</pub-id><pub-id pub-id-type="pmid">32255648</pub-id></element-citation></ref><ref id="bib0355"><label>71</label><mixed-citation publication-type="other" id="oref0355"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04377789?cond=COVID-19%26draw=14" id="intr0010">https://clinicaltrials.gov/ct2/show/NCT04377789?cond=COVID-19&#x00026;draw=14</ext-link>, accessed on 06/13/2020.</mixed-citation></ref><ref id="bib0360"><label>72</label><mixed-citation publication-type="other" id="oref0360"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04377789?cond=COVID-19%26draw=3%26rank=184" id="intr0015">https://clinicaltrials.gov/ct2/show/NCT04377789?cond=COVID-19&#x00026;draw=3&#x00026;rank=184</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0365"><label>73</label><mixed-citation publication-type="other" id="oref0365"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04375202?cond=COVID-19%26draw=2%26rank=61" id="intr0020">https://clinicaltrials.gov/ct2/show/NCT04375202?cond=COVID-19&#x00026;draw=2&#x00026;rank=61</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0370"><label>74</label><mixed-citation publication-type="other" id="oref0370"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04308317?cond=COVID-19%26draw=4%26rank=298" id="intr0025">https://clinicaltrials.gov/ct2/show/NCT04308317?cond=COVID-19&#x00026;draw=4&#x00026;rank=298</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0375"><label>75</label><mixed-citation publication-type="other" id="oref0375"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19%26draw=5%26rank=3" id="intr0030">https://clinicaltrials.gov/ct2/show/NCT04333550?cond=COVID-19&#x00026;draw=5&#x00026;rank=3</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0380"><label>76</label><mixed-citation publication-type="other" id="oref0380"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04359316?cond=COVID-19%26draw=2%26rank=78" id="intr0035">https://clinicaltrials.gov/ct2/show/NCT04359316?cond=COVID-19&#x00026;draw=2&#x00026;rank=78</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0385"><label>77</label><mixed-citation publication-type="other" id="oref0385"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04344444?cond=COVID-19%26draw=4%26rank=244" id="intr0040">https://clinicaltrials.gov/ct2/show/NCT04344444?cond=COVID-19&#x00026;draw=4&#x00026;rank=244</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0390"><label>78</label><mixed-citation publication-type="other" id="oref0390"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04332094?cond=COVID-19%26draw=4%26rank=273" id="intr0045">https://clinicaltrials.gov/ct2/show/NCT04332094?cond=COVID-19&#x00026;draw=4&#x00026;rank=273</ext-link>, accessed on 05/15/2020.</mixed-citation></ref><ref id="bib0395"><label>79</label><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>J.B.</given-names></name></person-group><article-title>A risk-benefit assessment of iron-chelation therapy</article-title><source>DrugSafety</source><volume>17</volume><year>1997</year><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.2165/00002018-199717060-00006</pub-id></element-citation></ref><ref id="bib0400"><label>80</label><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>M.</given-names></name><name><surname>Akbarzadeh</surname><given-names>A.</given-names></name></person-group><article-title>Improvement of desferrioxamine B production of <italic>Streptomyces pilosus</italic> ATCC 19797 with use of protease inhibitor and minerals related to its activity</article-title><source>Indian J. Clin. Biochem.</source><volume>27</volume><issue>3</issue><year>2012</year><fpage>274</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">26405387</pub-id></element-citation></ref><ref id="bib0405"><label>81</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Georgiou</surname><given-names>N.A.</given-names></name></person-group><article-title>Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin</article-title><source>J. Infect. Dis.</source><volume>181</volume><issue>2</issue><year>2000</year><fpage>484</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2004.03.003</pub-id><pub-id pub-id-type="pmid">10669330</pub-id></element-citation></ref><ref id="bib0410"><label>82</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Naesens</surname></name></person-group><article-title>Role of human hypoxanthine guanine phosphoribosyl transferase in activation of the antiviral agent T-705 (favipiravir)</article-title><source>Mol. Pharmacol.</source><volume>84</volume><year>2013</year><fpage>615</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1124/mol.113.087247</pub-id><pub-id pub-id-type="pmid">23907213</pub-id></element-citation></ref><ref id="bib0415"><label>83</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Takahashi</surname></name></person-group><article-title><italic>In vitro</italic> and <italic>in vivo</italic> activities of T-705 and oseltamivir against influenza virus</article-title><source>Antivir. Chem. Chemother.</source><volume>14</volume><year>2003</year><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1177/095632020301400502</pub-id><pub-id pub-id-type="pmid">14694986</pub-id></element-citation></ref><ref id="bib0420"><label>84</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T.</given-names></name></person-group><article-title>T-705 (Favipiravir) suppresses tumor necrosis factor <italic>&#x003b1;</italic> production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug</article-title><source>Acta Virol.</source><volume>61</volume><issue>1</issue><year>2017</year><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.4149/av_2017_01_48</pub-id><pub-id pub-id-type="pmid">28105854</pub-id></element-citation></ref><ref id="bib0425"><label>85</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Furuta</surname></name></person-group><article-title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</article-title><source>Antiviral Res.</source><volume>100</volume><issue>2</issue><year>2013</year><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.09.015\</pub-id><pub-id pub-id-type="pmid">24084488</pub-id></element-citation></ref><ref id="bib0430"><label>86</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Daikoku</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</article-title><source>Pharmacol. Ther.</source><volume>209</volume><year>2020</year><object-id pub-id-type="publisher-id">107512</object-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107512</pub-id></element-citation></ref><ref id="bib0435"><label>87</label><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>A.</given-names></name><name><surname>Terkeltaub</surname><given-names>M.D.</given-names></name></person-group><article-title>Colchicine Update: 2008</article-title><source>Semin. Arthritis Rheum.</source><volume>38</volume><issue>6</issue><year>2009</year><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2008.08.006</pub-id><pub-id pub-id-type="pmid">18973929</pub-id></element-citation></ref><ref id="bib0440"><label>88</label><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name></person-group><article-title>The influence of natural products upon drug discovery</article-title><source>Nat. Prod. Rep.</source><volume>17</volume><year>2000</year><fpage>215</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1039/a902202c</pub-id><pub-id pub-id-type="pmid">10888010</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p id="par0220">This work is partially supported by the <funding-source id="gs0005">Agricultural Research Service - United States Department of Agriculture (USDA ARS)</funding-source>, Specific Cooperative Agreement No. 58-6060-6-015.</p></ack></back></article>